ObesityNCT02450097
Metabolic and Hormonal Effects of 5:2 Intermittent Fasting
A study testing Caloric restriction in people with Obesity and Diabetes Type 2, run by Karolinska University Hospital at 1 site in Sweden.
Trial summary
The aim of the present study is to investigate in subjects with and without type 2 diabetes the effect of calorie restriction (CR) according to the 5:2 method for 6 months (every week two days caloric fasting with 500 calories for women and 600 calories for men and five days of normal caloric intake) on risk markers… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Obesity, Diabetes Type 2
- What is being tested?
- Caloric restriction
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteSweden
- Study dates
- Dec 2013to Dec 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age > 18 years of age.
- Subjects without diabetes with BMI 23-37.
- Patients with Type 2 diabetes and diabetes duration between 0.5-12 years and BMI 25-37
Who cannot join
- BMI below 23
- Waist circumference 80 cm or less for women and 94 cm or less than for men.
- Total fat percent of body weight less than 23%.
- Treatment with insulin and sulfonylurea drugs.
- Chronic kidneys disease (CKD) stage 4 and 5 (eGFR <30 ml/min).
- Pregnancy and breast-feed.
Show all 10Show fewer
- Active athletes.
- History of eating disorder.
- Participation in another ongoing study.
- If participant is not eligible to complete the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Metabolic and Hormonal Effects of 5:2 Intermittent Fasting in Patients With Type 2 Diabetes and Subjects With Adiposity
The aim of the present study is to investigate in subjects with and without type 2 diabetes the effect of calorie restriction (CR) according to the 5:2 method for 6 months (every week two days caloric fasting with 500 calories for women and 600 calories for men and five days of normal caloric intake) on risk markers for cardiovascular disease and certain cancers (hyperinsulinemia, insulin resistance, IGF-1, IGFBP-1, IGFBP-2, glucose, HbA1c, blood lipids, markers of inflammation and oxidative stress) and on peptides regulating glucose metabolism and appetite as well as the effect on blood pressure, body composition, waist- and hip- circumference. DNA will also be analysed at the start and after 6 months to investigate any epigenetic effects.
After completed study there will be a follow up after additional 6 months.
Read the detailed description
Background: It is well known that the majority of the population in the western world eats too much calories in relation to physical activity. This results in increased body weight, insulin resistance and premature age-related diseases such as diabetes, hypertension, cardiovascular disease, even dementia and certain types of cancer like colon cancer and breast cancer.
Several studies have shown that calorie restriction (CR) reduces the risk for cardiovascular disease, diabetes and Alzheimer's disease. Animal studies have shown that CR reduces insulin like growth factor-1 (IGF-1) levels, cancer incidence and prolong lifespan. Chronic every day CR decreases blood lipids and glucose, blood pressure, insulin resistance and inflammatory markers. It has been shown to reduce incidence of atherosclerosis directly correlated to the CR and not to weight reduction. However, only few studies have investigated the effect of periodic CR in healthy subjects with adiposity and in patients with type 2 diabetes. Moreover, no studies to our knowledge have studied if there is any gender differences in the metabolic response to periodic CR or if the response is dependent on the degree of adiposity and metabolic disturbance. Since it for many people is very difficult to every day reduce caloric intake , the new method to reduce it to 25% of the normal intake during two days a week is of a great interest to study regarding the metabolic and hormonal effects in men and women.
Questions to be answered; Do women and men respond differently to this diet and do subjects with type 2 diabetes respond differently to those without diabetes. How many subjects can continue to follow this new diet during the 6 months study and during further 6 months follow up?
Primary end points: Change from baseline in fasting serum insulin, C-peptide and insulin like factor binding protein-1 (IGFBP-1) in 6 months.
Secondary end points: Changes in body composition including body fat percentage, blood pressure, blood lipids, blood glucose, markers of inflammation, oxidative stress and hormones regulating appetite, and changes in wellbeing, diet habits and physical activity.
Material/Subjects: 100 subjects will be recruited via media and from outpatient clinics for diabetes care at Karolinska University Hospital and Sophiahemmet Hospital in Stockholm, Sweden.
Method: The subjects who have given informed consent will get a questionnaire regarding well-being, physical activity, life style, family history of diabetes, obesity, hypertension, cardiovascular disease, cancer and of dementia, previous medical and weight history and drugs used. The subjects will be examined by a doctor at a screening visit and blood and urine samples will be taken. Waist and hip circumference, blood pressure and pulse at sitting position after 10 minutes rest, estimation of the body composition, percent body fat and free fat mass (muscle mass) will be registered. The subjects will also respond to a questionnaire regarding diet habits and a meal diary during three ordinary days. A group of 10 to 15 subjects will be informed at a meeting with the doctors, nurses and dietitian about the diet (given 25 examples) during the 2 days of calorie restriction and recommended diet (Mediterranean or Nordic diet) during the other 5 days in the week. The subjects will respond to questions regarding hunger, fullness and satiety during the 2 days of calorie restriction (500 for women and 600 for men) and register which of 25 possible given meals they select during the calorie restriction days every week for 26 weeks. After 6 weeks there will be a follow up with new blood and urine tests, wellbeing questionnaires and after 3 and 6 months new blood and urine test, physical examination, questionnaires regarding physical activity, wellbeing, and diet habits and meal diary during 3 days. After completed study there will be a follow up after additional 6 months when participant are free to choose too continue with CR or not.
At all visits blood pressure, pulse; waist and hip circumference and body composition will be registered. The blood and urine samples will be taken in the morning after an overnight fast and after a day of normal diet. The blood and urine samples will be stored in a local human sample bank at the hospital for later analysis after the study is closed.
- Conditions
- Obesity, Diabetes Type 2
- Being tested
- Caloric restriction
- Medical subject headings
- Obesity, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Caloric restrictionOther
| Study group | Role | What they receive |
|---|---|---|
| Lifestyle counseling | Other | Intermittent Caloric restriction in 3 Groups:
I- 40 patients with diabetes type 2 BMI 25.1-37 II- 40 non diabetic over weight subjects with BMI 25.1-37 III- 20 non diabetic subject with BMI 23.1 - 25 and visceral fat Receives: Other: Caloric restriction |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in fasting serum insulin in 6 months.
Serum insulin will be measured using a radioimmunoassay (RIA; Pharmacia insulin RIA 100, Pharmacia Diagnostics, Uppsala, Sweden).
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 May 2015 (estimated)
- Study startDec 2013
- Primary completionNov 2017
- Study completionDec 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Karolinska University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Karolinska University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kerstin Brismar, Karolinska University Hospital
- Investigators
- Kerstin Brismar, Professor, Principal investigator, Karolinska University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02450097
- Sponsor's protocol ID
- Dnr2013/1618-31/3
- Status last verified
- Dec 2017
- First submitted
- 24 Mar 2014
- Last updated
- 15 Dec 2017
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Lira-Junior R, Aogain MM, Crncalo E, Ekberg NR, Chotirmall SH, Pettersson S, Gustafsson A, Brismar K, Bostanci N. Effects of intermittent fasting on periodontal inflammation and subgingival microbiota. J Periodontol. 2024 Jul;95(7):640-649. doi: 10.1002/JPER.23-0676. Epub 2024 Apr 24.
PubMed 38655661
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Metabolic and Hormonal Effects of 5:2 Intermittent Fasting in Patients With Type 2 Diabetes and Subjects With Adiposity
- ClinicalTrials.gov ID
- NCT02450097
- Acronym / sponsor ID
- Dnr2013/1618-31/3
- Conditions
- Obesity, Diabetes Type 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Karolinska University HospitalUniversity, hospital or other
- Study start
- Dec 2013
- Primary completion
- Nov 2017 (actual)
- Study completion
- Dec 2017 (actual)
- First posted
- 21 May 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the present study is to investigate in subjects with and without type 2 diabetes the effect of calorie restriction (CR) according to the 5:2 method for 6 months (every week two days caloric fasting with 500 calories for women and 600 calories for men and five days of normal caloric intake) on risk markers for cardiovascular disease and certain cancers (hyperinsulinemia, insulin resistance, IGF-1, IGFBP-1, IGFBP-2, glucose, HbA1c, blood lipids, markers of inflammation and oxidative stress) and on peptides regulating glucose metabolism and appetite as well as the effect on blood pressure, body composition, waist- and hip- circumference. DNA will also be analysed at the start and after 6 months to investigate any epigenetic effects.
After completed study there will be a follow up after additional 6 months.
Detailed description
Background: It is well known that the majority of the population in the western world eats too much calories in relation to physical activity. This results in increased body weight, insulin resistance and premature age-related diseases such as diabetes, hypertension, cardiovascular disease, even dementia and certain types of cancer like colon cancer and breast cancer.
Several studies have shown that calorie restriction (CR) reduces the risk for cardiovascular disease, diabetes and Alzheimer's disease. Animal studies have shown that CR reduces insulin like growth factor-1 (IGF-1) levels, cancer incidence and prolong lifespan. Chronic every day CR decreases blood lipids and glucose, blood pressure, insulin resistance and inflammatory markers. It has been shown to reduce incidence of atherosclerosis directly correlated to the CR and not to weight reduction. However, only few studies have investigated the effect of periodic CR in healthy subjects with adiposity and in patients with type 2 diabetes. Moreover, no studies to our knowledge have studied if there is any gender differences in the metabolic response to periodic CR or if the response is dependent on the degree of adiposity and metabolic disturbance. Since it for many people is very difficult to every day reduce caloric intake , the new method to reduce it to 25% of the normal intake during two days a week is of a great interest to study regarding the metabolic and hormonal effects in men and women.
Questions to be answered; Do women and men respond differently to this diet and do subjects with type 2 diabetes respond differently to those without diabetes. How many subjects can continue to follow this new diet during the 6 months study and during further 6 months follow up?
Primary end points: Change from baseline in fasting serum insulin, C-peptide and insulin like factor binding protein-1 (IGFBP-1) in 6 months.
Secondary end points: Changes in body composition including body fat percentage, blood pressure, blood lipids, blood glucose, markers of inflammation, oxidative stress and hormones regulating appetite, and changes in wellbeing, diet habits and physical activity.
Material/Subjects: 100 subjects will be recruited via media and from outpatient clinics for diabetes care at Karolinska University Hospital and Sophiahemmet Hospital in Stockholm, Sweden.
Method: The subjects who have given informed consent will get a questionnaire regarding well-being, physical activity, life style, family history of diabetes, obesity, hypertension, cardiovascular disease, cancer and of dementia, previous medical and weight history and drugs used. The subjects will be examined by a doctor at a screening visit and blood and urine samples will be taken. Waist and hip circumference, blood pressure and pulse at sitting position after 10 minutes rest, estimation of the body composition, percent body fat and free fat mass (muscle mass) will be registered. The subjects will also respond to a questionnaire regarding diet habits and a meal diary during three ordinary days. A group of 10 to 15 subjects will be informed at a meeting with the doctors, nurses and dietitian about the diet (given 25 examples) during the 2 days of calorie restriction and recommended diet (Mediterranean or Nordic diet) during the other 5 days in the week. The subjects will respond to questions regarding hunger, fullness and satiety during the 2 days of calorie restriction (500 for women and 600 for men) and register which of 25 possible given meals they select during the calorie restriction days every week for 26 weeks. After 6 weeks there will be a follow up with new blood and urine tests, wellbeing questionnaires and after 3 and 6 months new blood and urine test, physical examination, questionnaires regarding physical activity, wellbeing, and diet habits and meal diary during 3 days. After completed study there will be a follow up after additional 6 months when participant are free to choose too continue with CR or not.
At all visits blood pressure, pulse; waist and hip circumference and body composition will be registered. The blood and urine samples will be taken in the morning after an overnight fast and after a day of normal diet. The blood and urine samples will be stored in a local human sample bank at the hospital for later analysis after the study is closed.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Lifestyle counseling | Other | Other: Caloric restrictionIntermittent Caloric restriction in 3 Groups: I- 40 patients with diabetes type 2 BMI 25.1-37 II- 40 non diabetic over weight subjects with BMI 25.1-37 III- 20 non diabetic subject with BMI 23.1 - 25 and visceral fat |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age > 18 years of age.
- Subjects without diabetes with BMI 23-37.
- Patients with Type 2 diabetes and diabetes duration between 0.5-12 years and BMI 25-37
Key exclusion criteria (10 listed)
- BMI below 23
- Waist circumference 80 cm or less for women and 94 cm or less than for men.
- Total fat percent of body weight less than 23%.
- Treatment with insulin and sulfonylurea drugs.
- Chronic kidneys disease (CKD) stage 4 and 5 (eGFR <30 ml/min).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Caloric restriction | Other | Lifestyle counseling |
Primary outcome
Change from baseline in fasting serum insulin in 6 months.
Time frame: 6 months
Serum insulin will be measured using a radioimmunoassay (RIA; Pharmacia insulin RIA 100, Pharmacia Diagnostics, Uppsala, Sweden).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2017.
- Derived from this study: PubMed 38655661Lira-Junior R, Aogain MM, Crncalo E, Ekberg NR, Chotirmall SH, Pettersson S, Gustafsson A, Brismar K, Bostanci N. Effects of intermittent fasting on periodontal inflammation and subgingival microbiota. J Periodontol. 2024 Jul;95(7):640-649. doi: 10.1002/JPER.23-0676. Epub 2024 Apr 24.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kerstin Brismar, Professor principal investigator
Karolinska University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Caloric restriction in people with Obesity and Diabetes Type 2, run by Karolinska University Hospital at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Dec 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in fasting serum insulin in 6 months. (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02450097, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2017.